Related Experiment Video
Updated: Aug 8, 2026
Analysis of Cell Cycle Position in Mammalian Cells
Published on: January 21, 2012
Mammalian G1 and G2 phase checkpoints
1Laboratory of Molecular Pharmacology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Abstract:
This present review explores the mechanisms for DNA damage induced G1 and G2 arrest in mammalian cells. The complexity of the TP53 pathway is attested to by the variety of genes regulated by TP53, many of which require further investigation to bring their importance into focus. One gene intensely studied, p21, has been linked to the G1 arrest mechanism and may, like TP53, be involved in some aspect of DNA repair. The outcome of TP53 activation for cell survival is equally complex and relies much upon cellular context and the type of DNA damaging agent employed. Although TP53 may participate in sensing DNA damage, additional components are likely to be required. Much of the focus on defining the mechanism of G2 arrest in mammalian cells has concentrated on the cyclin B1/CDC2 kinase. Activation of this kinase is suppressed by DNA damage, and this may result from the imposition of inhibitory phosphorylations on the CDC2 kinase as well as downregulation of cyclin B1 levels. The logical point where the G2 checkpoint interacts with the CDC2-CDC25C autocatalytic loop to prevent CDC2 activation remains to be defined and could involve inhibition of CDC25C-CDC2 interaction. It is hoped that moving upstream of CDC2 towards the point where DNA damage is sensed by the cell will uncover homologues of yeast components implicated in G2 checkpoint control. The finding that certain G2 checkpoint abrogators preferentially synergize with DNA damaging agents in cells with defective TP53 provides a potential pharmacological route through which TP53 defective cells might be targeted for destruction. Further exploration of this vulnerability might prove useful for future anti-cancer drug discovery efforts.
Insights
This review details DNA damage responses, focusing on G1 and G2 cell cycle arrest mechanisms in mammalian cells. Understanding the TP53 pathway and its role in DNA repair and cell survival is crucial for cancer therapy development.
Area of Science:
- Cellular and Molecular Biology
- Genetics and Genomics
- Cancer Research
Background:
- Mammalian cells possess intricate mechanisms to arrest the cell cycle at G1 and G2 phases following DNA damage.
- The tumor suppressor protein TP53 (also known as p53) plays a central role in these responses, regulating numerous downstream genes.
- The precise molecular events governing G1 and G2 arrest, including the involvement of p21 and the cyclin B1/CDC2 kinase complex, are complex and context-dependent.
Purpose of the Study:
- To explore the mechanisms of DNA damage-induced G1 and G2 arrest in mammalian cells.
- To highlight the complexity of the TP53 pathway and its regulated genes, such as p21.
- To discuss the factors influencing cell survival outcomes after TP53 activation and the potential for targeting TP53-defective cancer cells.
Main Methods:
- Review of existing literature on DNA damage response pathways.
- Analysis of the roles of key proteins like TP53, p21, cyclin B1, and CDC2 in cell cycle regulation.
- Exploration of the interplay between DNA damage sensing and cell cycle checkpoint activation.
Main Results:
- TP53 regulates diverse genes, with p21 implicated in G1 arrest and potentially DNA repair.
- Cellular context and DNA damaging agent type significantly influence TP53's impact on cell survival.
- DNA damage suppresses cyclin B1/CDC2 kinase activation, possibly via inhibitory phosphorylations and reduced cyclin B1 levels, affecting G2 arrest.
- The precise interaction point in the CDC2-CDC25C loop for G2 arrest remains to be fully elucidated.
Conclusions:
- Further research is needed to fully understand the TP53 pathway and its role in DNA repair and cell cycle control.
- Identifying upstream components of the G2 checkpoint could reveal novel therapeutic targets.
- Targeting vulnerabilities in TP53-defective cancer cells, potentially through G2 checkpoint abrogators, offers a promising strategy for anti-cancer drug discovery.
Related Concept Videos
02:11The Cell Cycle Control System
02:15M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
02:19The Spindle Assembly Checkpoint
Many proteins function together to control the spindle assembly checkpoint. Mutations affecting these proteins may allow cells to proceed into anaphase prematurely, resulting in the...
02:11The Cell Cycle Control System
02:15M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
01:28The Cell Cycle Control System
Cyclins and cyclin-dependent kinases (Cdks) are the primary cell cycle regulators and function at the cell...